Literature DB >> 20824490

Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells.

Lei Lv1, Xing-Yuan Xiao, Zhao-Hui Gu, Fu-Qing Zeng, Lu-Qi Huang, Guo-Song Jiang.   

Abstract

The ubiquitin specific peptidase 22 (USP22) is a positive regulator of the growth of tumors. However, little is known about the impact of USP22 knockdown on the growth of human bladder cells. In the present study, we designed a series of asymmetric interfering RNAs (aiRNAs) and compared the efficacy of aiRNA and conventional symmetric interfering RNA (siRNA) in the silencing of USP22 expression and the growth of human bladder EJ cells in vitro and in vivo. In comparison with transfection with the USP22-specific siRNA, transfection with 15/21 aiRNA was more potent in down-regulating the USP22 expression and inhibiting EJ cell proliferation in vitro. Furthermore, transfection with 15/21 aiRNA induced higher frequency of EJ cells arrested at the G0/G1 phases, but did not trigger EJ cell apoptosis. Moreover, transfection with either the siRNA or 15/21 aiRNA up-regulated the expression of p53 and p21, but down-regulated the expression of cyclin E and Mdm2 in EJ cells. The up-regulated p53 expression induced by the specific siRNA or aiRNA was abrogated by induction of Mdm2 over-expression. In addition, treatment with the specific siRNA or aiRNA inhibited the growth of implanted human bladder tumors in mice and the aiRNA had more potent anti-tumor activity in vivo. Therefore, our data suggest that knockdown of USP22 expression by the aiRNA may down-regulate the expression of Mdm2 and cyclin E, resulting in the up-regulated expression of p53 and p21 and leading to cell cycling arrest and inhibition of human bladder EJ cell proliferation. Our findings indicate that the USP22-specific aiRNA may be a novel approach for the intervention of human bladder tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20824490     DOI: 10.1007/s11010-010-0585-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  31 in total

Review 1.  RNA interference.

Authors:  Gregory J Hannon
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

Review 2.  Prevention of bladder cancer: a review.

Authors:  John T Leppert; Oleg Shvarts; Kelly Kawaoka; Ron Lieberman; Arie S Belldegrun; Allan J Pantuck
Journal:  Eur Urol       Date:  2005-12-28       Impact factor: 20.096

3.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.

Authors:  Gennadi V Glinsky; Olga Berezovska; Anna B Glinskii
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

4.  Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26.

Authors:  Yaara Ofir-Rosenfeld; Kristy Boggs; Dan Michael; Michael B Kastan; Moshe Oren
Journal:  Mol Cell       Date:  2008-10-24       Impact factor: 17.970

5.  EdU, a new thymidine analogue for labelling proliferating cells in the nervous system.

Authors:  Fatemah Chehrehasa; Adrian C B Meedeniya; Patrick Dwyer; Greger Abrahamsen; Alan Mackay-Sim
Journal:  J Neurosci Methods       Date:  2008-10-18       Impact factor: 2.390

6.  Bladder cancer detection, treatment and outcomes: opportunities and challenges.

Authors:  David M Latini; Seth P Lerner; Sally W Wade; David W Lee; Diane Z Quale
Journal:  Urology       Date:  2009-12-05       Impact factor: 2.649

7.  Inactivation of HAUSP in vivo modulates p53 function.

Authors:  N Kon; Y Kobayashi; M Li; C L Brooks; T Ludwig; W Gu
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

8.  Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells.

Authors:  Qin-Chuan Liang; Hua Xiong; Zhen-Wei Zhao; Dong Jia; Wei-Xin Li; Huai-Zhou Qin; Jian-Ping Deng; Li Gao; Hua Zhang; Guo-Dong Gao
Journal:  Cancer Lett       Date:  2008-09-14       Impact factor: 8.679

9.  Regulation of cell cycle progression and gene expression by H2A deubiquitination.

Authors:  Heui-Yun Joo; Ling Zhai; Chunying Yang; Shuyi Nie; Hediye Erdjument-Bromage; Paul Tempst; Chenbei Chang; Hengbin Wang
Journal:  Nature       Date:  2007-10-03       Impact factor: 49.962

10.  Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection.

Authors:  Masayuki Sano; Malgorzata Sierant; Makoto Miyagishi; Mahito Nakanishi; Yasuomi Takagi; Shizuyo Sutou
Journal:  Nucleic Acids Res       Date:  2008-09-09       Impact factor: 16.971

View more
  31 in total

Review 1.  Flickin' the ubiquitin switch: the role of H2B ubiquitylation in development.

Authors:  Duncan Edward Wright; Chen-Yi Wang; Cheng-Fu Kao
Journal:  Epigenetics       Date:  2011-10-01       Impact factor: 4.528

2.  USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma.

Authors:  Jun Li; Zhou Wang; Yu Li
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-25       Impact factor: 4.553

3.  USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer.

Authors:  Shengli Wang; Xinping Zhong; Chunyu Wang; Hao Luo; Lin Lin; Hongmiao Sun; Ge Sun; Kai Zeng; Renlong Zou; Wei Liu; Ning Sun; Huijuan Song; Wensu Liu; Qiang Zhang; Zhixuan Liao; Xiaochun Teng; Tingting Zhou; Xun Sun; Yue Zhao
Journal:  Cell Death Differ       Date:  2020-06-03       Impact factor: 15.828

4.  USP22 controls multiple signaling pathways that are essential for vasculature formation in the mouse placenta.

Authors:  Evangelia Koutelou; Li Wang; Andria C Schibler; Hsueh-Ping Chao; Xianghong Kuang; Kevin Lin; Yue Lu; Jianjun Shen; Collene R Jeter; Andrew Salinger; Marenda Wilson; Yi Chun Chen; Boyko S Atanassov; Dean G Tang; Sharon Y R Dent
Journal:  Development       Date:  2019-02-22       Impact factor: 6.868

5.  Low-intensity pulsed ultrasound activates ERK1/2 and PI3K-Akt signalling pathways and promotes the proliferation of human amnion-derived mesenchymal stem cells.

Authors:  Li Ling; Tianqin Wei; Lianli He; Yaping Wang; Yan Wang; Xiushan Feng; Wenqian Zhang; Zhengai Xiong
Journal:  Cell Prolif       Date:  2017-09-22       Impact factor: 6.831

6.  Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma.

Authors:  Hui Wang; Yong-Ping Li; Jiang-Hao Chen; Shi-Fang Yuan; Ling Wang; Ju-Liang Zhang; Qing Yao; Nan-Lin Li; Jie-Fang Bian; Jing Fan; Jun Yi; Rui Ling
Journal:  Tumour Biol       Date:  2013-02-15

7.  MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinoma.

Authors:  Huadong Zhao; Haili Tang; Qike Huang; Bo Qiu; Xiaomin Liu; Dong Fan; Li Gong; Hang Guo; Chong Chen; Shixiong Lei; Lu Yang; Jianguo Lu; Guoqiang Bao
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

8.  ShRNA-mediated silencing of the ubiquitin-specific protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyngeal carcinoma.

Authors:  Ya-Jing Zhuang; Zhi-Wei Liao; Hong-Wei Yu; Xian-Lu Song; Yuan Liu; Xing-Yuan Shi; Xiao-Dan Lin; Tong-Chong Zhou
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

9.  Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics.

Authors:  Jun Liang; Xianli Zhang; Shao Xie; Xiuping Zhou; Qiong Shi; Jinxia Hu; Weifeng Wang; Weifeng Qi; Rutong Yu
Journal:  Med Oncol       Date:  2014-02-27       Impact factor: 3.064

10.  USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.

Authors:  Randy S Schrecengost; Jeffry L Dean; Jonathan F Goodwin; Matthew J Schiewer; Mark W Urban; Timothy J Stanek; Robyn T Sussman; Jessica L Hicks; Ruth C Birbe; Rossitza A Draganova-Tacheva; Tapio Visakorpi; Angelo M DeMarzo; Steven B McMahon; Karen E Knudsen
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.